Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the provided excerpt. The company reported a decrease in finance cost by 17% in FY26 compared to the previous year. Closing net debt for FY26 was INR 2,255 crores, which is 2x EBITDA and down two turns over the last two years, indicating deleveraging. The management discussed strategic capital expenditure of close to INR 300 crores largely on biologics and sterile injectables, funded presumably through internal accruals or existing resources. No statements indicate any plans for raising fresh capital th

Any current/future capex/capital investment/strategic investment?

INR 160-180 crores invested in developing a large biotech play (DS facility). INR 250 crores invested in Bhopal fill and finish site, which is expected to improve margins and open new markets once operational. A map facility set up at Bhopal, considered future-focused but delayed by 1 to 1.5 years. Additional plant investment for Swiss Parenterals with commissioning expected in April, doubling current parenteral capacity. No major CapEx planned for remediation related to EU GMP inspection; mainly procedural and training-related improvements. Capital expenditure focused on strategic g

Future growth expectations in sales/revenue/volumes?

International business: Latin America (LatAm) expected to grow faster in FY27 due to more new product approvals; Africa, Asia, and LatAm remain key geographies with stable mix (~30% Africa, 30% Asia, 25% LatAm). EU CDMO: No base case revenue expected in FY27; any revenue would be upside; major revenues anticipated from FY28 onwards. Domestic Formulations (DBF): Overall DBF growth around 11-12%; insulin and derma therapies already outperforming; cardiovascular (CVD) segment catching up; other oral anti-diabetic (OAD) therapies expected to require more time to catch up. Semaglutide segment: E

Future growth expectations in earnings/operating earnings/profits/EPS?

Eris Lifesciences expects DBF revenue growth at 1.3x of covered market growth in FY27 with DBF EBITDA margin steady at ~37%, and higher margin in H2 than H1. Consolidated revenue growth of 18-20% guided for international business in FY27 with EBITDA margin similar to FY26. Return on Capital Employed (ROCE) expected to improve from 15% in FY26 to 23-25% by FY28 as new assets start generating returns. EPS expected to accelerate with 10% growth in EBITDA leading to 34% PAT growth in FY26; similar EPS acceleration is anticipated in coming years. EU CDMO revenues not expected in FY27; a pot

IN US

Sale is live|00:00:00left today

ERIS Lifesciences LtdQ1 FY26Pharmaceuticals & Biotechnology

ERIS Lifesciences Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,461P/E: 42.8Market Cap: ₹19.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→International business: Latin America (LatAm) expected to grow faster in FY27 due to more new product approvals; Africa, Asia, and LatAm remain key geographies with stable mix (~30% Africa, 30% Asia, 25% LatAm).
→EU CDMO: No base case revenue expected in FY27; any revenue would be upside; major revenues anticipated from FY28 onwards.
→Domestic Formulations (DBF): Overall DBF growth around 11-12%; insulin and derma therapies already outperforming; cardiovascular (CVD) segment catching up; other oral anti-diabetic (OAD) therapies expected to require more time to catch up.
→Semaglutide segment: Early traction with market share growing; expect continued month-on-month buildup; pricing stable or minor corrections expected.
→Capital expenditure (biotech, fill-finish plants) to enable scaling, better margins, and new product launches in coming years.

Margin guidance

Category 3

→Eris Lifesciences expects DBF revenue growth at 1.3x of covered market growth in FY27 with DBF EBITDA margin steady at ~37%, and higher margin in H2 than H1.
→Consolidated revenue growth of 18-20% guided for international business in FY27 with EBITDA margin similar to FY26.
→Return on Capital Employed (ROCE) expected to improve from 15% in FY26 to 23-25% by FY28 as new assets start generating returns.
→EPS expected to accelerate with 10% growth in EBITDA leading to 34% PAT growth in FY26; similar EPS acceleration is anticipated in coming years.
→EU CDMO revenues not expected in FY27; a potential upside from FY28 onwards.
→Some margin softness expected in H1 FY27 due to Semaglutide launch expenses but recovery and margin improvement in H2 anticipated.
→Domestic Insulin and Derma therapies expected to continue outperforming; cardiovascular therapies improving; OAD therapy to catch up over time.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or future fundraising through debt or equity in the provided excerpt.
→The company reported a decrease in finance cost by 17% in FY26 compared to the previous year.
→Closing net debt for FY26 was INR 2,255 crores, which is 2x EBITDA and down two turns over the last two years, indicating deleveraging.
→The management discussed strategic capital expenditure of close to INR 300 crores largely on biologics and sterile injectables, funded presumably through internal accruals or existing resources.
→No statements indicate any plans for raising fresh capital through debt or equity in the near term.

Order book

The transcript does not provide specific quantitative details or figures regarding the current or expected order book or pending orders for Eris Lifesciences Limited. However, some related insights can be summarized: - The EU CDMO business has no impact on the existing order book; key contracts continue as planned. - A product commercialization expected in Q1 got delayed due to regulatory issues, affecting revenue timing but not the order book. - International business debtor days have reduced, indicating improved collections, which could positively impact order execution. - The company expects growth in Semaglutide (SEMA) sales with a month-on-month buildup, reflecting growing demand. - The Bhopal and Swiss Parenteral manufacturing capacities are under development and expected to contribute to order fulfillment and margin expansion once operational. No explicit order backlog numbers were disclosed in the excerpts provided.

Capex plans

Yes

→INR 160-180 crores invested in developing a large biotech play (DS facility).
→INR 250 crores invested in Bhopal fill and finish site, which is expected to improve margins and open new markets once operational.
→A map facility set up at Bhopal, considered future-focused but delayed by 1 to 1.5 years.
→Additional plant investment for Swiss Parenterals with commissioning expected in April, doubling current parenteral capacity.
→No major CapEx planned for remediation related to EU GMP inspection; mainly procedural and training-related improvements.
→Capital expenditure focused on strategic growth areas including biotech, parenterals, and insulin manufacturing, aiming to scale capacity and improve profitability.
→Expected capacity expansion in insulin cartridge line by H2 FY27 at Bhopal to support market share growth.

How does ERIS Lifesciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1ERIS Lifesciences Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like ERIS Lifesciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio